May 8, 2017
Teva’s and Active Biotech’s multiple sclerosis drug fails meeting primary endpoint
Teva Pharmaceutical Industries and Active Biotech have reported that the CONCERTO trial in patients with relapsing-remitting multiple sclerosis (RRMS) did not meet its primary endpoint.